Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 Aficamten clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Obstructive Hypertrophic Cardiomyopathy (oHCM) & Obstructive Hypertrophic Cardiomyopathy) and 1,996 total planned enrollment. 4 Phase 3 Aficamten trials are listed. 2 Aficamten clinical trials are actively recruiting at 23 U.S. sites across 18 states. Most recent activity: NCT06412666 (Jan 2030).
Where to Participate: All Aficamten Trial Sites in the U.S. (23 sites across 18 states)
Every actively recruiting Aficamtentrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
7 Aficamten clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 4 are marked completed.
Are Aficamten clinical trials recruiting in 2026?
Yes — 2 Aficamten trials are actively recruiting in 2026, with 23 U.S. sites across 18 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Aficamten being studied for?
Aficamten is being studied for Obstructive Hypertrophic Cardiomyopathy (oHCM), Obstructive Hypertrophic Cardiomyopathy, Healthy Participants, Symptomatic Hypertrophic Cardiomyopathy (HCM), Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy and 2 more. The trials are grouped by indication on this page.
What phase is Aficamten in?
Aficamten clinical trials span 4 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Aficamten clinical trials?
The lead sponsor across the most Aficamten trials is Cytokinetics, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Aficamtenas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.